 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH today announced a strategic collaboration with Daiichi Sankyo, Inc. Daiichi Sankyo to pursue regulatory approval and commercialization of the Guardant360 CDx blood test as a companion diagnostic for Enhertu fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody-drug conjugate ADC, being studied in the treatment of patients with advanced metastatic non-small cell lung cancer NSCLC. For patients with metastati 